Calcium channel blockers for hypertension: Dissecting the evidence for adverse effects

American Journal of Hypertension

Volumn 10, Issue 5 I, 1997, Pages 565-577

  Opie, Lionel H ^a,b  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

adverse effects; Calcium channel blocker; drug safety; hypertension; nifedipine; verapamil

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CATECHOLAMINE; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIURETIC AGENT; LONG ACTING DRUG; NIFEDIPINE; VERAPAMIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; CANCER RISK; CATECHOLAMINE BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; META ANALYSIS; PRIORITY JOURNAL; REMISSION; REVIEW; STROKE; SUSTAINED RELEASE PREPARATION;

EID: 0031010406     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(96)00508-0     Document Type: Article

References (84)

1. Pahor M, Guralnik JM, Salive ME, et al: Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996;9:695-699.
2. Alderman MH: More news about calcium antagonists. Am J Hypertension 1996;9:710-712.
3. Haynes RB, Lacoucière Y, Rabkin SW, et al: Report of the Canadian Hypertension Society Consensus Conference: 2 Diagnosis of hypertension in adults. Can Med Assoc J 1993;149:409-418.
4. Sacks HJ, Berrier J, Reitman D, et al: Meta-analyses of randomized controlled trials. N Engl J Med 1987; 316:450-455.
5. Thompson SG, Pocock SJ: Can meta-analyses be trusted? Lancet 1991;338:1127-1130.
6. Psaty BM, Heckbert SR, Koepsell TD, et al: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-625.
7. Frost PH, Davis BR, Burlando AJ, et al: Coronary artery disease risk factors in men and women aged 60 years and older. Findings from the Systolic Hypertension in Elderly Program. Circulation 1996;94:26-34.
8. Fischer Hansen J: The Danish Study Group on Verapamil in Myocardial Infarction. Treatment with verapamil during and after an acute myocardial infarction: A review based on the Danish verapamil infarction trials I and II. J Cardiovasc Pharmacol 1991;18(suppl 6):S20-S25.
9. Jick H, Derby LE, Gurewich V, Vasilakis K: The risk of myocardial infarction associated with antihypertensive drug treatment in persons with uncomplicated essential hypertension. Pharmacotherapy 1996;16:321-326.
10. Aursnes I, Litleskare I, Froyland H, Abdelnoor M: Association between various drugs used for hypertension and risk of acute myocardial infarction. Blood Pressure 1995;4:157-163.
11. GLANT Study: A 12-month comparison of ACE inhibitor and Ca antagonist therapy in mild to moderate essential hypertension. Hypertens Res 1995;18:235-244.
12. Gong L, Zhang W, Zhu Y, Zhu J, for the STONE Study: Shanghai Trial of Nifedipine in the Elderly. J Hypertens 1996;14:1237-1245.
13. Opie LH, for the STONE Study: Shanghai Trial of Hypertension in the Elderly (Meeting Report). Cardiovasc Drugs Therap 1996;10:467-468.
14. Furberg CD, Psaty BM, Meyer JV: Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92:1326-1331.
15. Muller J, Morrison J, Stone PH, et al: Nifedipine therapy for patients with threatened and acute myocardial infarction: a randomized, double-blind, placebo-controlled comparison. Circulation 1984;69:740-747.
16. Muller JE, Turi ZG, Pearl DL, et al: Nifedipine and conventional therapy for unstable angina pectoris: a randomized, double-blind comparison. Circulation 1984;69:728-739.
17. Goldbourt U, Behar S, Reicher-Reiss H, et al, for the SPRINT II Study: Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Reinfarction Israel Nifedipine Trial 2 Study. Arch Intern Med 1993;153:345-353.
18. Opie LH, Messerli FH: Nifedipine and mortality. Grave defects in the dossier. Circulation 1995;92:1068-1073.
19. Holland Interuniversity Nifedipine/Metoprolol Trial (HINT Study): Early treatment of unstable angina in the coronary care unit; a randomised, double-blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986;56:400-413.
20. Braun S, Boyko V, Behar S, et al: Calcium antagonists and mortality in patients with coronary artery disease: a cohort study of 11,575 patients. J Am Coll Cardiol 1996;28:7-11.
21. Koenig W, Lowel H, Lewis M, Hermann M: Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication. Results of the Augsburg myocardial infarction follow-up study. Eur Heart J 1996;17:1199Z-1206.
22. Multicenter Diltiazem Postinfarction Trial Research Group (MDPIT Study) : The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1983;319:385-392.
23. Rehnqvist N, Hjemdahl P, Billing E, et al, for the APSIS Study: The Angina Prognosis Study in Stockholm (AP-SIS). Effects of metoprolol vs verapamil in patients with stable angina pectoris. Eur Heart J 1996;17:76-81.
24. Yusuf S, Wittes J, Friedman L: Overview of results of randomized clinical trials in heart disease. II Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. JAMA 1988;260:2259-2263.
25. Dargie H J, Ford I, Fox K M, on behalf of the TIBET study group: Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J 1996; 17:104-112.
26. Secondary Prevention reinfarction Israeli Nifedipine Trial (SPRINT I Study): A randomized intervention trail of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-364.
27. Danish Study Group on Verapamil in Myocardial Infarction (DAVIT I Study): Verapamil in acute myocardial infarction. Br J Clin Pharmacol 1986;21:197S-204S.
28. Danish Study Group of Verapamil in Myocardial Infarction (DAVIT II Study) : The effects of verapamil on mortality and major events after myocardial infarction. The Danish Verapamil Infarction Trial II (DAVIT II). Am J Cardiol 1990;66:779-785.
29. Rengo F, Carbonin P, Pahor M, et al, for the CRIS Study: A controlled trial of verapamil in patients after acute myocardial infarction: results of Calcium Antagonist Reinfarction Italian Study (CRIS). Am J Cardiol 1996;77:365-369.
30. Boden WE, Krone RJ, Kleiger RE, et al: Electrocardiographic subset analysis of diltiazem administration on long-term outcome after acute myocardial infarction. Am J Cardiol 1991;67:335-342.
31. Boden WE, Fischer Hansen J, Lau J, Roberts R: Beneficial effect of heart rate-lowering calcium channel blockers (diltiazem, verapamil) on reducing long-term (12-18 month) cardiac death and nonfatal reinfarction in patients recovering from acute non-Q-wave myocardial infarction (abst). Circulation 1995;92 (suppl I):I-81.
32. Boden W, Messerli FH, Fischer Hansen J , Schectman KB: Heart rate-lowering calcium channel blockers (diltiazem, verapamil) do not adversely affect long-term cardiac death or non-fatal infarction in post-infarction patients: data pooled from 3 randomized, placebo-controlled clinical trials of 5,677 patients. Am J Cardiol 1996;27:319A.
33. Messerli F, Boden WE, Fischer Hansen J, Schechtman KB: Heart rate lowering calcium antagonists (HRL-CA) in hypertensive post MI patients. J Am Coll Cardiol 1996;27:178A.
34. Leenen FHH, Holliwell DL: Antihypertensive effect of felodipine associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992;69:639-645.
35. Pahor M, Guralnik JM, Conti M, et al: Long term survival and use of antihypertensive medications in older persons. J Am Geriat Soc 1995;43:1191-1197.
36. Pahor M, Guralnik JM, Furberg CD, et al: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347:1061-1065.
37. Gordon RD: Calcium antagonists and gastrointestinal haemorrhage: the balancing act. Lancet 1996;347:1056.
38. Medical Research Council Study: Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992;304:405-412.
39. Hole DJ, Hawthorne VM, McGhee SM, et al: Incidence of mortality from cancer in hypertensive patients. Br Med J 1993;306:609-611.
40. Taubes G: Epidemiology faces its limits. Science 1995; 269:164-169.
41. Rauwolfia derivatives and cancer. Lancet 1974;ii:701-702.
42. Boston Collaborative Drug Surveillance Program: Resperine and breast cancer. Lancet 1974;2:669-671.
43. Shapiro S, Parsells JL, Rosenberg L, et al: Risk of breast cancer in relation to the use of rauwolfia alkaloids. Eur J Clin Pharmacol 1984;26:143-146.
44. Hamet P: Cancer and hypertension. An unresolved issue. Hypertens 1996;28:321-324.
45. Gopalakrishna R, Barsky S: Tumour promotor-induced membrane-bound protein kinase C regulates hematogenous metastasis. Proc Natl Acad Sci 1988;85:612-616.
46. Lim R, Zaheer A: Phorbol ester stimulates rapid intracellular phosphorylation of GLIA maturation factor. Biochem Biophys Res Comm 1995;3:928-934.
47. De Jonge HW, Van Heugten HAA, Lamers JMJ: Signal transduction by the phosphatidylinositol cycle in the myocardium. J Mol Cell Cardiol 1995;27:93-106.
48. 2+-dependent signalling. Circ Res 1995;76:1-15.
49. Balakumaran A, Campbell GA, Moslen MT: Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol 1996;139:122-127.
50. Taylor JM, Simpson RU: Inhibition of cancer cell growth by calcium channel antagonists in the athymic mouse. Cancer Res 1992;52:2413-2418.
51. Lichtlen PR, Hugenholtz PG, Rafflenbeul W, et al, for the INTACT Study: Retardation of angiographic progression of coronary artery disease by nifedipine. Lancet 1990;335:1109-1113.
52. Agabiti-Rosei E, Muiesan ML, Romanelli G, et al: Similarities and differences in the antihypertensive effect of two calcium antagonist drugs, verapamil and nifedipine. J Am Coll Cardiol 1986;7:916-924.
53. Kailasam MT, Parmer RJ, Cervenka JH, et al: Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995;26:143-149.
54. Wallen NH, Held C, Rehnqvist N, Hjemdahl P: Platelet aggregability in vivo is attenuated by verapamil but not by metroprolol in patients with stable angina pectoris. Am J Cardiol 1995;75:1-6.
55. Nazzaro P, Manzari M, Merlo R, et al: Antihypertensive treatment with verapamil and amlodipine. Their effect on the functional autonomic and cardiovascular stress responses. Eur Heart J 1995;16:1227-1284.
56. Ruzicka M, Leenen FH: Relevance of 24 h blood pressure profile and sympathetic activity for outcome on short- versus long-acting 1,4-dihydropyridines. Am J Hypertens 1996;9:86-94.
57. Phillips RA, Ardeljan M, Shimabukuro S: Normalization of left ventricular mass and associated changes in neurohormones and atrial natriuretic peptide after 1 year of sustained nifedipine therapy for severe hypertension. J Am Coll Cardiol 1991;17:1595-1602.
58. Parmley WW, Nesto RW, Singh BN, et al: Attenuation of the circadian patterns of myocardial ischemia with nifedipine GITS in patients with chronic stable angina. J Am Coll Cardiol 1992;19:1380-1389.
59. Leenen FH, Fourney A: Comparison of the effects of amlodipine and diltiazem on 24-hour blood pressure, plasma catecholamines, and left ventricular mass. Am J Hypertens 1996;78:203-207.
60. Packer M, Nicod P, Khandheria BR: Randomized multicenter double-blind placebo-controlled evaluation of amlodipine in patients with mild-to-moderate heart failure (abstr). J Am Coll Cardiol 1991;17:274A.
61. Kleinbloesem CH, van Brummelen P, Danhof M, et al: Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodymanic effects in humans. Clin Pharmacol Ther 1987;41:26-30.
62. Messerli FH, Hamet P, Opie LH: Cardiotoxicity of calcium antagonists: Morbidity and mortality during therapy with long-acting agents (abst), 16th Scientific Meeting of the International Society of Hypertension, Glasgow, 1996.
63. Julius S: Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993;21:886-893.
64. Lindqvist M, Kahan T, Melcher A, Hjemdahl P: Acute and chronic calcium antagonist treatment elevates sympathetic activity in primary hypertension. Hypertension 1994;24:287-296.
65. Cappuccio FP, Markandu ND, Sagnella GA, et al: Effects of amlodipine on urinary sodium excretion, reninangiotensin-aldosterone system, a trial natriuretic peptide and blood pressure in essential hypertension. J Hum Hypertens 1991;5:511-519.
66. Lee DD, Rigonan K, Dequattro V: Increased blood pressure and neural tone in the silent ischemia of hypertension: disparate effects of immediate release nifedipine. J Am Coll Cardiol 1993;22:1438-1445.
67. JNC V: The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993; 153:154-183.
68. Chalmers J, Zanchetti A: The 1996 report of a World Health Organization expert committee on hypertension control. Hypertens 1996;14:929-933.
69. Furberg CD, Psaty BM: Should dihydropyridines be used as first-line drugs in the treatment of hypertension? Arch Intern Med 1995;155:2157-2161.
70. Materson BJ, Reda DJ, Cushman WC, et al: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. N Engl J Med 1993;328:914-921.
71. Kaplan NM: Do calcium antagonists cause myocardial infarction? Am J Cardiol 1996;77:81-82.
72. Neaton J D, Grimm R H, Prineas R J, et al, for the TOMH Study: Treatment of mild hypertension study (TOMH). Final results. JAMA 1993;270:713-724.
73. Zannad F, Matzinger A, Larche J: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996;9:633-643.
74. Chobanian AV: Calcium channel blockers. Lessons learned from MIDAS and other clinical trials (editorial). JAMA 1996;276:829-830.
75. Ekbom R, Dahlöf B, Hansson L, et al, for the STOP Study: Antihypertensive efficacy and side effects of three beta-blockers and a diuretic in elderly hypertensives: a report from the STOP-Hypertension study. J Hypertens 1992;10:1525-1530.
76. Systolic Hypertension in Elderly Program Study: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265:3255-3264.
77. Hoes AW, Grobbee DE, Lubsen J, et al: Diuretics, β-blockers, and the risk for sudden cardiac death in hypertensive patients. Ann Intern Med 1995;123:481-487.
78. Siscovick DS, Raghunathun TE, Psaty BM: Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-1857.
79. MRC Study: Medical Research Council trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
80. Leenen FH: 1.4-Dihydropyridines versus beta-blockers for hypertension: are either safe for the heart? Cardiovasc Drugs Ther 1996;10:307-402.
81. Packer M, O'Connor CM, Ghali JK, et al: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-1114.
82. Strom BL: Study designs available for pharmacoepidemiology studies, in Strom B (ed): Pharmacoepidemiology. New York, John Wiley & Sons, 1994, pp 15-27.
83. Lindholm LH, Tcherdakoff P, Zanchetti A: Safety aspects of treatment with lacidipine - a slow-onset, long-acting calcium antagonist. Blood Pressure 1996;5:241-249.
84. Furberg CD, Psaty BM: Corrections to the nifedipine meta-analysis. Circulation 1996;93:1475-1476.